152 related articles for article (PubMed ID: 8795084)
1. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
[TBL] [Abstract][Full Text] [Related]
2. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells.
Gallwitz B; Witt M; Fölsch UR; Creutzfeldt W; Schmidt WE
J Mol Endocrinol; 1993 Jun; 10(3):259-68. PubMed ID: 8396943
[TBL] [Abstract][Full Text] [Related]
3. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
[TBL] [Abstract][Full Text] [Related]
5. In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide.
Hinke SA; Manhart S; Speck M; Pederson RA; Demuth HU; McIntosh CH
Life Sci; 2004 Aug; 75(15):1857-70. PubMed ID: 15302229
[TBL] [Abstract][Full Text] [Related]
6. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
[TBL] [Abstract][Full Text] [Related]
7. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Holst JJ
BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
[TBL] [Abstract][Full Text] [Related]
8. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
[TBL] [Abstract][Full Text] [Related]
9. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
11. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
12. Structure/activity characterization of glucagon-like peptide-1.
Gallwitz B; Witt M; Paetzold G; Morys-Wortmann C; Zimmermann B; Eckart K; Fölsch UR; Schmidt WE
Eur J Biochem; 1994 Nov; 225(3):1151-6. PubMed ID: 7957206
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
[TBL] [Abstract][Full Text] [Related]
14. Lower glucose-dependent insulinotropic polypeptide (GIP) response but similar glucagon-like peptide 1 (GLP-1), glycaemic, and insulinaemic response to ancient wheat compared to modern wheat depends on processing.
Bakhøj S; Flint A; Holst JJ; Tetens I
Eur J Clin Nutr; 2003 Oct; 57(10):1254-61. PubMed ID: 14506486
[TBL] [Abstract][Full Text] [Related]
15. Circulation and degradation of GIP and GLP-1.
Deacon CF
Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
Mentlein R; Gallwitz B; Schmidt WE
Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
[TBL] [Abstract][Full Text] [Related]
17. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
[TBL] [Abstract][Full Text] [Related]
18. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.
Brubaker PL; Drucker DJ
Recept Channels; 2002; 8(3-4):179-88. PubMed ID: 12529935
[TBL] [Abstract][Full Text] [Related]
19. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach.
Lippl F; Kircher F; Erdmann J; Allescher HD; Schusdziarra V
Regul Pept; 2004 Jun; 119(1-2):93-8. PubMed ID: 15093702
[TBL] [Abstract][Full Text] [Related]
20. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
